CN109528777A - By the application for the composition that Lactobacillus rhamnosus and 2`- fucosyllactose form - Google Patents
By the application for the composition that Lactobacillus rhamnosus and 2`- fucosyllactose form Download PDFInfo
- Publication number
- CN109528777A CN109528777A CN201811585852.6A CN201811585852A CN109528777A CN 109528777 A CN109528777 A CN 109528777A CN 201811585852 A CN201811585852 A CN 201811585852A CN 109528777 A CN109528777 A CN 109528777A
- Authority
- CN
- China
- Prior art keywords
- parts
- lactobacillus rhamnosus
- composition
- fucosyllactose
- freeze
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000218588 Lactobacillus rhamnosus Species 0.000 title claims abstract description 119
- 239000000203 mixture Substances 0.000 title claims abstract description 44
- 239000000843 powder Substances 0.000 claims abstract description 42
- 206010061218 Inflammation Diseases 0.000 claims abstract description 26
- 230000004054 inflammatory process Effects 0.000 claims abstract description 26
- HWHQUWQCBPAQQH-BWRPKUOHSA-N 2-fucosyllactose Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@H]([C@H](O)CO)[C@H](O)[C@@H](O)C=O HWHQUWQCBPAQQH-BWRPKUOHSA-N 0.000 claims abstract description 17
- 235000015097 nutrients Nutrition 0.000 claims abstract description 12
- 238000002360 preparation method Methods 0.000 claims abstract description 12
- 239000013589 supplement Substances 0.000 claims abstract description 12
- 235000013305 food Nutrition 0.000 claims abstract description 8
- 210000002490 intestinal epithelial cell Anatomy 0.000 claims abstract description 8
- 239000006041 probiotic Substances 0.000 claims abstract description 7
- 235000018291 probiotics Nutrition 0.000 claims abstract description 7
- 235000013350 formula milk Nutrition 0.000 claims abstract description 5
- 235000013336 milk Nutrition 0.000 claims abstract description 4
- 239000008267 milk Substances 0.000 claims abstract description 4
- 210000004080 milk Anatomy 0.000 claims abstract description 4
- 229940079593 drug Drugs 0.000 claims abstract description 3
- 239000003814 drug Substances 0.000 claims abstract description 3
- 235000013402 health food Nutrition 0.000 claims abstract description 3
- 229940062827 2'-fucosyllactose Drugs 0.000 claims abstract 15
- HWHQUWQCBPAQQH-UHFFFAOYSA-N 2-O-alpha-L-Fucosyl-lactose Natural products OC1C(O)C(O)C(C)OC1OC1C(O)C(O)C(CO)OC1OC(C(O)CO)C(O)C(O)C=O HWHQUWQCBPAQQH-UHFFFAOYSA-N 0.000 claims abstract 15
- SNFSYLYCDAVZGP-UHFFFAOYSA-N UNPD26986 Natural products OC1C(O)C(O)C(C)OC1OC1C(OC2C(OC(O)C(O)C2O)CO)OC(CO)C(O)C1O SNFSYLYCDAVZGP-UHFFFAOYSA-N 0.000 claims abstract 15
- 229960005486 vaccine Drugs 0.000 claims description 31
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 12
- 241000894006 Bacteria Species 0.000 claims description 11
- 229940088594 vitamin Drugs 0.000 claims description 10
- 239000011782 vitamin Substances 0.000 claims description 10
- 239000002994 raw material Substances 0.000 claims description 9
- 230000008439 repair process Effects 0.000 claims description 9
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 claims description 7
- 240000007594 Oryza sativa Species 0.000 claims description 7
- 235000007164 Oryza sativa Nutrition 0.000 claims description 7
- 230000006378 damage Effects 0.000 claims description 7
- 235000009566 rice Nutrition 0.000 claims description 7
- 102100026189 Beta-galactosidase Human genes 0.000 claims description 6
- 244000077995 Coix lacryma jobi Species 0.000 claims description 6
- 235000007354 Coix lacryma jobi Nutrition 0.000 claims description 6
- 244000000626 Daucus carota Species 0.000 claims description 6
- 235000002767 Daucus carota Nutrition 0.000 claims description 6
- 239000004375 Dextrin Substances 0.000 claims description 6
- 229920001353 Dextrin Polymers 0.000 claims description 6
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 6
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 claims description 6
- 108010059881 Lactase Proteins 0.000 claims description 6
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 6
- 235000007688 Lycopersicon esculentum Nutrition 0.000 claims description 6
- 240000003768 Solanum lycopersicum Species 0.000 claims description 6
- 244000062793 Sorghum vulgare Species 0.000 claims description 6
- 239000005862 Whey Substances 0.000 claims description 6
- 102000007544 Whey Proteins Human genes 0.000 claims description 6
- 108010046377 Whey Proteins Proteins 0.000 claims description 6
- 108010005774 beta-Galactosidase Proteins 0.000 claims description 6
- 229910000019 calcium carbonate Inorganic materials 0.000 claims description 6
- 239000005018 casein Substances 0.000 claims description 6
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 claims description 6
- 235000021240 caseins Nutrition 0.000 claims description 6
- 235000019425 dextrin Nutrition 0.000 claims description 6
- 235000021433 fructose syrup Nutrition 0.000 claims description 6
- 235000021255 galacto-oligosaccharides Nutrition 0.000 claims description 6
- 150000003271 galactooligosaccharides Chemical class 0.000 claims description 6
- 229940116108 lactase Drugs 0.000 claims description 6
- 239000008101 lactose Substances 0.000 claims description 6
- 235000019713 millet Nutrition 0.000 claims description 6
- 235000020183 skimmed milk Nutrition 0.000 claims description 6
- 239000011734 sodium Substances 0.000 claims description 6
- 229910052708 sodium Inorganic materials 0.000 claims description 6
- WGIWBXUNRXCYRA-UHFFFAOYSA-H trizinc;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [Zn+2].[Zn+2].[Zn+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O WGIWBXUNRXCYRA-UHFFFAOYSA-H 0.000 claims description 6
- 229940068475 zinc citrate Drugs 0.000 claims description 6
- 239000011746 zinc citrate Substances 0.000 claims description 6
- 235000006076 zinc citrate Nutrition 0.000 claims description 6
- OMSYGYSPFZQFFP-UHFFFAOYSA-J zinc pyrophosphate Chemical compound [Zn+2].[Zn+2].[O-]P([O-])(=O)OP([O-])([O-])=O OMSYGYSPFZQFFP-UHFFFAOYSA-J 0.000 claims description 6
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 claims description 5
- 108091005804 Peptidases Proteins 0.000 claims description 5
- 239000004365 Protease Substances 0.000 claims description 5
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims description 5
- 108010073771 Soybean Proteins Proteins 0.000 claims description 5
- 240000008042 Zea mays Species 0.000 claims description 5
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 claims description 5
- 235000002017 Zea mays subsp mays Nutrition 0.000 claims description 5
- 235000005822 corn Nutrition 0.000 claims description 5
- 229940001941 soy protein Drugs 0.000 claims description 5
- 235000012424 soybean oil Nutrition 0.000 claims description 5
- 239000003549 soybean oil Substances 0.000 claims description 5
- 241000186660 Lactobacillus Species 0.000 claims description 4
- 239000004227 calcium gluconate Substances 0.000 claims description 4
- 229960004494 calcium gluconate Drugs 0.000 claims description 4
- 235000013927 calcium gluconate Nutrition 0.000 claims description 4
- NEEHYRZPVYRGPP-UHFFFAOYSA-L calcium;2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Ca+2].OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O NEEHYRZPVYRGPP-UHFFFAOYSA-L 0.000 claims description 4
- 239000006071 cream Substances 0.000 claims description 4
- 229940039696 lactobacillus Drugs 0.000 claims description 4
- 241000195493 Cryptophyta Species 0.000 claims description 3
- 102000004190 Enzymes Human genes 0.000 claims description 3
- 108090000790 Enzymes Proteins 0.000 claims description 3
- 235000010216 calcium carbonate Nutrition 0.000 claims description 3
- 229940088598 enzyme Drugs 0.000 claims description 3
- 239000011435 rock Substances 0.000 claims description 3
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical class OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 2
- 235000009754 Vitis X bourquina Nutrition 0.000 claims description 2
- 235000012333 Vitis X labruscana Nutrition 0.000 claims description 2
- 240000006365 Vitis vinifera Species 0.000 claims description 2
- 235000014787 Vitis vinifera Nutrition 0.000 claims description 2
- NEEHYRZPVYRGPP-IYEMJOQQSA-L calcium gluconate Chemical compound [Ca+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O NEEHYRZPVYRGPP-IYEMJOQQSA-L 0.000 claims description 2
- 238000004108 freeze drying Methods 0.000 claims description 2
- 229960003563 calcium carbonate Drugs 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000010977 jade Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 16
- 230000036541 health Effects 0.000 abstract description 2
- 238000011160 research Methods 0.000 abstract description 2
- 230000003993 interaction Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 39
- 239000002158 endotoxin Substances 0.000 description 25
- 229920006008 lipopolysaccharide Polymers 0.000 description 25
- 210000001842 enterocyte Anatomy 0.000 description 13
- 230000004083 survival effect Effects 0.000 description 12
- 230000001413 cellular effect Effects 0.000 description 11
- 230000002757 inflammatory effect Effects 0.000 description 10
- 230000006749 inflammatory damage Effects 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 7
- 235000020256 human milk Nutrition 0.000 description 6
- 210000004251 human milk Anatomy 0.000 description 6
- 230000035699 permeability Effects 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 238000004977 Hueckel calculation Methods 0.000 description 5
- 208000027418 Wounds and injury Diseases 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 102000003777 Interleukin-1 beta Human genes 0.000 description 4
- 108090000193 Interleukin-1 beta Proteins 0.000 description 4
- 102000004889 Interleukin-6 Human genes 0.000 description 4
- 108090001005 Interleukin-6 Proteins 0.000 description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- 230000000968 intestinal effect Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 2
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 2
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000013401 experimental design Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000009629 microbiological culture Methods 0.000 description 2
- 150000002772 monosaccharides Chemical class 0.000 description 2
- 229920001542 oligosaccharide Polymers 0.000 description 2
- 150000002482 oligosaccharides Chemical class 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
- 102400000888 Cholecystokinin-8 Human genes 0.000 description 1
- 101800005151 Cholecystokinin-8 Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 102000051366 Glycosyltransferases Human genes 0.000 description 1
- 108700023372 Glycosyltransferases Proteins 0.000 description 1
- 102000004890 Interleukin-8 Human genes 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 241000917009 Lactobacillus rhamnosus GG Species 0.000 description 1
- OVRNDRQMDRJTHS-RTRLPJTCSA-N N-acetyl-D-glucosamine Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-RTRLPJTCSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 230000001741 anti-phlogistic effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000012930 cell culture fluid Substances 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000004637 cellular stress Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 201000010897 colon adenocarcinoma Diseases 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 235000014103 egg white Nutrition 0.000 description 1
- 210000000969 egg white Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000000751 protein extraction Methods 0.000 description 1
- 238000000197 pyrolysis Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 150000004043 trisaccharides Chemical class 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/123—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
- A23C9/1234—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt characterised by using a Lactobacillus sp. other than Lactobacillus Bulgaricus, including Bificlobacterium sp.
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/13—Fermented milk preparations; Treatment using microorganisms or enzymes using additives
- A23C9/1307—Milk products or derivatives; Fruit or vegetable juices; Sugars, sugar alcohols, sweeteners; Oligosaccharides; Organic acids or salts thereof or acidifying agents; Flavours, dyes or pigments; Inert or aerosol gases; Carbonation methods
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/16—Agglomerating or granulating milk powder; Making instant milk powder; Products obtained thereby
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/175—Rhamnosus
Abstract
The invention discloses the applications for the composition being made of Lactobacillus rhamnosus and 2'- fucosyllactose, belong to technical field of health care food.The present invention provides the compositions being made of Lactobacillus rhamnosus and 2'- fucosyllactose to have the application in the drug or health food or food for repairing human intestinal epithelial cells' inflammation damnification function in preparation.The present invention also provides a kind of baby formula milk powder containing the composition being made of Lactobacillus rhamnosus and 2'- fucosyllactose, infant nutrient replenishers, infant's diatery supplement and probiotics preparations.The present invention utilizes 2'- fucosyllactose by Lactobacillus rhamnosus in research discovery the composition, and two-way interaction can obtain the effect for repairing human intestinal epithelial cells' inflammation damnification function.The composition is suitable for repairing human intestinal epithelial cells' inflammation damnification.
Description
Technical field
The present invention relates to the applications for the composition being made of Lactobacillus rhamnosus and 2 '-fucosyllactoses, belong to health care
Food technology field.
Background technique
Human milk is the most natural ultimate food of baby, nutriment and bioactive ingredients rich in, including albumen
Matter, fat, carbohydrate, minerals, vitamin and S-IgA, taurine etc..Each component content in human milk
It is moderate, ratio be suitable for be conducive to baby's early growth and development and subsequent healthy growth, and have promote baby intestinal, nerve,
The phylogenetic effect such as immune.HMOs is the third solid component abundant in human milk after lactose and lipid, but due to not
It is easy digestion, so directly nutritive value is lower.They are synthesized in mammary gland by glycosyl transferase, are made of 5 kinds of monosaccharide:
Glucose (Glc), galactolipin (Gal), n- acetylglucosamine (GlcNAc), rock algae (Fuc) and sialic acid.So far, matter
Spectrometry has detected 200 multiple and different HMO monomer structures, range monosaccharide moieties from 3 to 14, wherein a structure more than 130
It has been determined.It is 2- fucosyllactose (2 '-FL) that HMO content is highest in most of breast milks, this is a kind of by glucose, half
The trisaccharide of lactose and fucose composition, concentration is about 2-3g/L of its content in breast milk, can reach 8g/L.
Many researchs are pointed out, although the nonnutritive value of HMOs, it plays unique and important in neonatal development
Effect.Since 2 '-FL are oligosaccharide the most abundant in most of breast feeding women's milk, and it makees with Immune enhancement
With, thus become breast milk oligosaccharide of greatest concern.
Summary of the invention
The present invention provides a kind of applications of composition being made of Lactobacillus rhamnosus and 2 '-fucosyllactoses, adopt
Technical solution is as follows:
The purpose of the present invention is to provide a kind of compositions being made of Lactobacillus rhamnosus and 2 '-fucosyllactoses to exist
Prepare the application having in the drug for repairing human intestinal epithelial cells' inflammation damnification function.
Another object of the present invention is to provide a kind of combinations being made of Lactobacillus rhamnosus and 2 '-fucosyllactoses
Object has the application in the health food for repairing human intestinal epithelial cells' inflammation damnification function in preparation.
Another object of the present invention is to provide a kind of combinations being made of Lactobacillus rhamnosus and 2 '-fucosyllactoses
Object has the application in the food for repairing human intestinal epithelial cells' inflammation damnification function in preparation.Food described herein refers to commonly
Food.
Preferably, the composition is made of Lactobacillus rhamnosus freeze-dried vaccine powder and 2 '-fucosyllactoses；Wherein: mouse
The mass ratio of Lee's sugar lactobacillus freeze-dried vaccine powder and 2 '-fucosyllactoses is 1:(0.1-0.4)；Lactobacillus rhamnosus freeze-dried vaccine powder
Total viable count of middle Lactobacillus rhamnosus is no less than 1011CFU/g。
It is highly preferred that the composition is made of Lactobacillus rhamnosus freeze-dried vaccine powder and 2 '-fucosyllactoses；Wherein:
The mass ratio of Lactobacillus rhamnosus freeze-dried vaccine powder and 2 '-fucosyllactoses is 1:0.4；Mouse in Lactobacillus rhamnosus freeze-dried vaccine powder
The total viable count of Lee's sugar lactobacillus is no less than 1011CFU/g。
Another object of the present invention is to provide a kind of containing being made of Lactobacillus rhamnosus and 2 '-fucosyllactoses
The baby formula milk powder of composition.
Another object of the present invention is to provide a kind of containing being made of Lactobacillus rhamnosus and 2 '-fucosyllactoses
The infant nutrient replenishers of composition.
Preferably, the infant nutrient replenishers are by skimmed milk powder, PURE WHEY, oligofructose, compound dimension life
Element, zinc citrate, calcium carbonate, soybean oil, casein sodium, isolated soy protein, 2 '-fucosyllactoses and rhamnose cream bar
Bacterium composition；The parts by weight of each raw material are as follows: 90 parts -100 parts of skimmed milk powder, 35 parts -40 parts of PURE WHEY, and oligofructose 10
- 12 parts of part, 0.1 part -0.15 part of multi-vitamins, 0.25 part -0.3 part of zinc citrate, 0.30 part -0.35 part of calcium carbonate, soybean
3.5 parts -4.0 parts of oil, 7.5 parts -8.0 parts of casein sodium, 3.2 parts -3.5 parts of isolated soy protein, 2 '-fucosyllactoses
0.1 part -0.48 part, 1 part -1.2 parts of Lactobacillus rhamnosus freeze-dried vaccine powder；Rhamnose cream in the Lactobacillus rhamnosus freeze-dried vaccine powder
Total viable count of bacillus is no less than 1011CFU/g。
It is highly preferred that the infant nutrient replenishers are by skimmed milk powder, PURE WHEY, oligofructose, compound dimension
Raw element, zinc citrate, calcium carbonate, soybean oil, casein sodium, isolated soy protein, 2 '-fucosyllactoses and rhamnose cream
Bacillus composition；The parts by weight of each raw material are as follows: 98 parts of skimmed milk powder, 38 parts of PURE WHEY, and 12 parts of oligofructose, compound dimension
Raw 0.15 part of element, 0.28 part of zinc citrate, 0.32 part of calcium carbonate, 3.8 parts of soybean oil, 7.5 parts of casein sodium, isolated soy egg
White 3.5 parts, 2 ' -0.4 part of fucosyllactoses, 1.2 parts of Lactobacillus rhamnosus freeze-dried vaccine powder；The Lactobacillus rhamnosus freeze-drying
Total viable count of Lactobacillus rhamnosus is no less than 10 in bacterium powder11CFU/g。
Another object of the present invention is to provide a kind of containing being made of Lactobacillus rhamnosus and 2 '-fucosyllactoses
Infant's diatery supplement of composition.
Preferably, infant's diatery supplement is by rice, fructose syrup, millet, adlay, corn, carrot, tomato, Portugal
Grape Calciofon, zinc pyrophosphate, multi-vitamins, oligofructose, galactooligosaccharide, lactase, protease, Lactobacillus rhamnosus and
2 '-fucosyllactoses；The parts by weight of each raw material are as follows: 55 parts -65 parts of rice, 4-8 parts of fructose syrup, 20 part -22 of millet
Part, 5 parts -8 parts of adlay, 10 parts -12 parts of corn, 6 parts -10 parts of carrot, 5 parts -8 parts of tomato, 10 parts -15 parts of calcium gluconate,
1.8 parts -2.5 parts of zinc pyrophosphate, 0.1 part -0.15 part of multi-vitamins, 4 parts -5 parts of oligofructose, 0.6 part of galactooligosaccharide -
1.0 parts, 2 parts -3 parts of lactase, 1 part -2 parts of protease, 1.2 parts -1.5 parts of Lactobacillus rhamnosus freeze-dried vaccine powder and 2 '-fucoses
0.12 part -0.6 part of base lactose；Total viable count of Lactobacillus rhamnosus is no less than in the Lactobacillus rhamnosus freeze-dried vaccine powder
1011CFU/g。
It is highly preferred that infant's diatery supplement be by rice, fructose syrup, millet, adlay, corn, carrot, tomato,
Calcium gluconate, zinc pyrophosphate, multi-vitamins, oligofructose, galactooligosaccharide, lactase, protease, Lactobacillus rhamnosus
With 2 '-fucosyllactoses；The parts by weight of each raw material are as follows: 60 parts of rice, 5 parts of fructose syrup, and 20 parts of millet, adlay 5
Part, it is 10 parts of corn, 7 parts of carrot, 5 parts of tomato, 15 parts of calcium gluconate, 2 parts of zinc pyrophosphate, 0.15 part of multi-vitamins, low
4.5 parts of Fructooligosaccharides, 0.8 part of galactooligosaccharide, 3 parts of lactase, 1.5 parts of protease, 1.5 parts of Lactobacillus rhamnosus freeze-dried vaccine powder and
2 ' -0.6 part of fucosyllactoses；Total viable count of Lactobacillus rhamnosus is no less than in the Lactobacillus rhamnosus freeze-dried vaccine powder
1011 CFU/g。
Contain the group being made of Lactobacillus rhamnosus and 2 '-fucosyllactoses it is a further object of the present invention to provide a kind of
Close the probiotics preparation of object.
Preferably, it is made of Lactobacillus rhamnosus, 2 '-fucosyllactoses, oligofructose and resistant dextrin, each raw material
Parts by weight are as follows: 15 parts -20 parts of Lactobacillus rhamnosus freeze-dried vaccine powder, 2 ' -1.5 parts -8 parts of fucosyllactoses, oligofructose
35 parts -40 parts and 30 parts -40 parts of resistant dextrin；Total viable bacteria of Lactobacillus rhamnosus in the Lactobacillus rhamnosus freeze-dried vaccine powder
Number no less than 1011 CFU/g。
It is highly preferred that 2 '-fucosyllactoses, oligofructose and resistant dextrin form, each raw material by Lactobacillus rhamnosus
Parts by weight it is as follows: 20 parts of Lactobacillus rhamnosus freeze-dried vaccine powder, 2 ' -8 parts of fucosyllactoses, 40 parts of oligofructose and resistance
35 parts of dextrin；Total viable count of Lactobacillus rhamnosus is no less than 10 in the Lactobacillus rhamnosus freeze-dried vaccine powder11CFU/g。
The invention has the advantages that:
The present invention provides a kind of composition being made of Lactobacillus rhamnosus and 2 '-fucosyllactoses, the present invention is logical
It crosses the study found that Lactobacillus rhamnosus has injury repair effect to human intestinal epithelial cells' model of inflammation damnification, and is adding
After the intervention of 2 '-FL, the inflammation damnification repair ability of Lactobacillus rhamnosus is significantly increased, and illustrates that 2 '-FL can promote rhamnose
Both lactobacillus repairs inflammation damnification, i.e., can mutually acting synergistically, it is significantly more to colon epithelial cell inflammation damnification to obtain
The effect of reparation, therefore, the composition of Lactobacillus rhamnosus provided by the invention and 2 '-FL, which have, repairs enterocyte damage
Effect, inflammation damnification repair ability be embodied in enhancing enterocyte inflammatory model survival ability, alleviate enterocyte
Inflammatory reaction reduces enterocyte high-permeability etc. and can additionally obtain and increases intestinal beneficial bacterium proliferation and stick
Effect.
It is found by cell experiment, LPS (lipopolysaccharides) induces the survival rate of Caco-2 cellular inflammation damage model by 49%
(LPS group) is promoted to 60%-75% (2 '-FL intervention group), and LPS induces the inflammatory factor of Caco-2 cellular inflammation damage model
Expression significantly reduces, and LPS induces the cell LDH emission levels of Caco-2 cellular inflammation damage model by 811.33U/L
(LPS group) is reduced to 473.01U/L-585.33U/L (2 '-FL intervention group), and MDA production quantity is by 2.16mmol/mg protein
(LPS group) is reduced to 1.40mmol/mg-1.87mmol/mg (2 '-FL intervention group).
Detailed description of the invention
Fig. 1 is the survival rate of Lactobacillus rhamnosus and 2 '-FL to Caco-2 cell.
Fig. 2 is that Lactobacillus rhamnosus and 2 '-FL intervene Caco-2 Cellular inflammatory factor expression level.
Fig. 3 is the influence of Lactobacillus rhamnosus and 2 '-FL to Caco-2 cell permeability and inflammatory damage reparation；A in figure
For cell LDH emission levels；B is that MDA generates level.
Specific embodiment
The present invention will be further described combined with specific embodiments below, but the present invention should not be limited by the examples.
Embodiment 1
One, experimental method
1, material
Lactobacillus rhamnosus CICC20255 is purchased from Chinese industrial Microbiological Culture Collection administrative center (CICC).
2 '-FL are purchased from Shanghai Xiang Geng development in science and technology Co., Ltd.
LPS (lipopolysaccharides) is purchased from Sigma-Aldrich (Shanghai) trade Co., Ltd (sigma).
2, the culture of Caco-2 cell
Human colon adenocarcinoma cell Caco-2 is grown on containing 1% dual anti-, 10% serum (FBS) DMEM in high glucose culture medium
In, at 37 DEG C, 5%CO2It is cultivated in incubator.2-3 days replacement cell culture fluids carry out cell passage to cell fusion 80%.
3, the preparation of Lactobacillus rhamnosus CICC20255 bacteria suspension
Lactobacillus rhamnosus CICC20255 is inoculated into the MRS broth bouillon of improvement, in 37 DEG C of constant temperature after mixing
12-14h is cultivated in incubator, is inoculated into the MRS culture medium of improvement with 2% bacterium amount that connects, and activates for two generations.8000r/min from
Bacterium mud is collected after heart 5min, sterilized physiological saline is added is resuspended and is centrifuged and washed, until bacterium mud is creamy white state.
The bacterium mud after washing is diluted to 10 with the DMEM culture medium of filtration sterilization9The bacteria suspension of CFU/g is spare.
4, LPS induces the building of Caco-2 Cellular inflammatory damage model
By cell inoculation in 96 orifice plates, 200 holes μ L/, every hole cell quantity is about 2 × 105It is a, it is complete that 100 μ L are added
Culture solution, by culture plate put culture in the incubator (at 37 DEG C, 5%CO2Under conditions of stablize overnight or > 5 hours).Discard training
The endless full nutrient solution Nature enemy 12h of 200 μ LDMEM is added in every hole after nutrient solution, and rear every hole is added at the LPS that concentration is 1 μ g/mL
Manage Caco-2 cell for 24 hours.
5, CCK8 method detects Lactobacillus rhamnosus and 2 '-FL to the survival rate of Caco-2 cell
After Caco-2 Cellular inflammatory Establishing an injured model, according to table 1 carry out experimental design grouping, every group of incubation for 24 hours, gently
Each hole supernatant is sucked, 10% 37 DEG C of (v/v) cck8 solution is added and is protected from light dissolution 1.5h, each hole absorbance is measured at 450nm
(OD value).
The grouping of 1 experimental design of table
Note: LPS, 2 '-FL additive amounts and Lactobacillus rhamnosus inoculum concentration in upper table are in every milliliter of DMEM culture medium
Additive amount.
6, it is horizontal to intervene Caco-2 Cellular inflammatory factor expression by ELISA method measurement Lactobacillus rhamnosus and 2 '-FL
With it is described previously modeled and intervened after, take cell culture fluid in each hole, draw supernatant after 3000r centrifugation 5min
Liquid.IL-1 β, IL-6, TNF-α MBP enzyme linked immuno-adsorbent assay (ELISA) are operated by kit specification.
7, the intervention of Lactobacillus rhamnosus and 2 '-FL to Caco-2 cell permeability
The measurement of LDH emission levels: it operates requirement to specifications using colorimetric kit and is measured.
The measurement of MDA production quantity: MDA production quantity is measured using TBARS method.It is described above by Caco-2 cell into
Row modeling and after intervening, collects cell and cell pyrolysis liquid is added is cracked.By after cell cracking solution and TBARS it is anti-
After answering liquid to be sufficiently mixed with 5:4 volume ratio, 95 DEG C of incubation 20min after isopropyl alcohol extracting pigment is added, is measured at 532nm and are inhaled
Luminosity.In addition, extracting total protein of cell with total protein extraction kit and measuring.
Two, experimental result
1, the survival rate of Lactobacillus rhamnosus and 2 '-FL to Caco-2 cell
This application is compared with the prior art, and after Lactobacillus rhamnosus and 2 '-FL are intervened, can be increased anti-inflammatory activity, be made
It has the characteristic for improving LPS induction Caco-2 cellular inflammation high penetration model survival rate.Table 2, Fig. 1 Lactobacillus rhamnosus and 2 '
- FL is to the survival rate of Caco-2 cell, * P < 0.05vs LPS group in figure.
As shown in Figure 1, Caco-2 cell, after the LPS of final concentration of 1 μ g/mL carries out modeling processing, cell survival rate is aobvious
Work drops to 49.18%.After being intervened using the Lactobacillus rhamnosus ATCC53103 and 2 '-FL of 4 groups of different formulations, survival
Rate significantly rises, influence of the 2 '-FL to the survival rate of cell and dose proportional example relationship；Shadow of the HMO to cell survival rate
Maximum is rung, improves 1.52 times compared with LPS group.
The survival rate of 2 Lactobacillus rhamnosus of table and 2 '-FL to Caco-2 cell
2, it is horizontal to intervene Caco-2 Cellular inflammatory factor expression by Lactobacillus rhamnosus and 2 '-FL
Table 3, it is horizontal that Fig. 2 is that Lactobacillus rhamnosus and 2 '-FL intervene Caco-2 Cellular inflammatory factor expression, * P in figure <
0.05vs LPS group.
The unconventionality expression of the inflammatory cytokines such as IL-1 β, IL-6, IL-8 and TNF-α is to lead to intestinal tissue intercellular tight
The main reason for connection loss and cell epithelia barrier injury.As shown in Fig. 2, IL-6, IL-1 β and the TNF-α of LPS group cell
Secretion dramatically increases, and after Lactobacillus rhamnosus and 2 '-FL are intervened, the expression of inflammatory factor is significantly reduced, and illustrates the composition
With anti-inflammatory activity.Wherein the antiphlogistic effects of 2 '-FL middle dose groups and high dose group are the most significant, compared with LPS inflammation group,
IL-1 β expression reduces 27.91% and 81.40%, and IL-6 level reduces 40.00% and 50.70%, and TNF-α drops
Low 60.74% and 56.51%.Therefore it can confirm that the composition of Lactobacillus rhamnosus and 2 '-FL have to enterocyte
Inflammation has relaxation effect, can effectively enhance the anti-inflammatory activity of enterocyte.
It is horizontal (pg/mL) that 3 Lactobacillus rhamnosus of table and 2 '-FL intervene Caco-2 Cellular inflammatory factor expression
3, the intervention of Lactobacillus rhamnosus and 2 '-FL to Caco-2 cell permeability and inflammatory damage reparation
Under normal circumstances, LDH is a kind of enzyme being stabilized in enterocyte matter, stress be damaged in cell by the external world
Wound can overflow after causing permeability of cell membrane to enhance from cell interior, therefore be usually used in assessing cellular stress degree of injury.MDA is
Intracellular unsaturated fatty acid occurs peroxidization and generates generated oxidation final product, has stronger bio-toxicity,
It is commonly used for one of the bionidicator of degree of assessment cell oxidative damage.It is discharged in the prior art commonly using LDH and MDA
Level repairs degree to assess enterocyte high penetration and inflammatory damage.This experiment by the Lactobacillus rhamnosus prepared and
2 '-FL compositions intervene the inflammation damnification model of Caco-2 cell, it was demonstrated that the composition can play repair cell inflammation
The effect of damage.Concrete outcome is as follows:
Table 4, Fig. 3 Lactobacillus rhamnosus and 2 '-FL to Caco-2 cell permeability and inflammatory damage reparation influence (* P <
0.05 vs LPS group), Fig. 3 A is cell LDH emission levels；Fig. 3 B is that MDA generates level.As shown in Figure 3A, LPS model group
It is obviously improved for more normal group of the emission levels of LDH in cell, for 2.16 times normally organized.Lactobacillus rhamnosus and 2 '-FL intervene
Group LDH emission levels are remarkably decreased, especially 2 '-FL middle dosages and high dose group, reduce by 39.95% He respectively compared with LPS group
41.70%.Fig. 3 B illustrates the influence of Lactobacillus rhamnosus and 2 '-FL to Caco-2 cell MDA production quantity, has phase with Fig. 3 A
As trend, i.e. the MDA of LPS group generates that horizontal relatively normal group is significant to be increased, and 2 '-FL middle dosages and high dose group are compared with LPS group
It is remarkably decreased, reduces 35.19% and 32.41% compared with LPS group respectively.Illustrate Lactobacillus rhamnosus and the composition tool of 2 '-FL
Play the role of repairing enterocyte high-permeability and inflammation damnification.
4 Lactobacillus rhamnosus of table and 2 '-FL generate horizontal and LDH emission levels influences to Caco-2 cell MDA
The human intestinal epithelial to inflammation damnification of Lactobacillus rhamnosus in the composition of Lactobacillus rhamnosus of the present invention and 2 '-FL
Cell model has an injury repair effect, and 2 '-FL promote Lactobacillus rhamnosus to play the effect of reparation inflammation damnification, but the work
The Lactobacillus rhamnosus for being not limited to specific a certain model is played, the Lactobacillus rhamnosus of disposable type is with 2 '-FL's
Composition, which all enough obtains, to be had the effect of repairing enterocyte high-permeability and inflammation damnification.The present invention is in order to further test
Card can buy the commercialization Lactobacillus rhamnosus obtained: Lactobacillus rhamnosus CICC6001 (purchase with two plants by commercial sources
From Chinese industrial Microbiological Culture Collection administrative center (CICC)) and Lactobacillus rhamnosus ATCC7469, according to the method described above into
Row identical experiment, as a result, it has been found that: the composition of Lactobacillus rhamnosus CICC6001 and 2 '-FL；Lactobacillus rhamnosus ATCC7469
All have the effect of repairing enterocyte high-permeability and inflammation damnification, to sum up, all models with the composition of 2 '-FL
Lactobacillus rhamnosus is suitable for the present invention.
Embodiment 2
The present embodiment illustrates the infant nutrient replenishers using Lactobacillus rhamnosus and 2 '-FL composition, heavy
It is as shown in table 5 to measure component.Lactobacillus rhamnosus in the present embodiment is freeze-dried vaccine powder, and the total viable count of Lactobacillus rhamnosus is no less than
1×1011 CFU/g。
5 infant nutrient of table supplements agent prescription
Experiments verify that discovery, which should contain Lactobacillus rhamnosus and the replenishers of 2 '-FL, has reparation enterocyte high pass
The effect of permeability and inflammation damnification.
Embodiment 3
The present embodiment illustrates the probiotics preparation using Lactobacillus rhamnosus and 2 '-FL composition, components by weight percent
It see the table below shown in 6.Lactobacillus rhamnosus in the present embodiment is freeze-dried vaccine powder, the total viable count of Lactobacillus rhamnosus is no less than 1 ×
1011CFU/g。
The formula of 6 probiotics preparation of table
Experiments verify that discovery, which should contain Lactobacillus rhamnosus and the probiotics preparation of 2 '-FL, has reparation enterocyte
The effect of high-permeability and inflammation damnification.
Embodiment 4
The present embodiment, which is illustrated, supplements diatery supplement using the infant nutrient of Lactobacillus rhamnosus and 2 '-FL composition,
Components by weight percent see the table below described in 7.Lactobacillus rhamnosus in the present embodiment is freeze-dried vaccine powder, and the total viable count of Lactobacillus rhamnosus is not
Less than 1 × 1011CFU/g。
The formula of 7 infant nutrient of table supplement diatery supplement
Have reparation enteric epithelium thin experiments verify that discovery should contain Lactobacillus rhamnosus and the nutritional supplementation diatery supplement of 2 '-FL
The effect of born of the same parents' high-permeability and inflammation damnification.
Although the present invention has been disclosed in the preferred embodiment as above, it is not intended to limit the invention, any to be familiar with this
The people of technology can do various changes and modification, therefore protection of the invention without departing from the spirit and scope of the present invention
Range should subject to the definition of the claims.
Claims (10)
1. the composition being made of Lactobacillus rhamnosus and 2'- fucosyllactose has in preparation repairs human intestinal epithelial cells' inflammation
The drug or the application in health food or food that disease damages function.
2. being applied described in claim 1, which is characterized in that the composition is by Lactobacillus rhamnosus freeze-dried vaccine powder and 2'- rock algae
Glycosyl lactose composition；Wherein: the mass ratio of Lactobacillus rhamnosus freeze-dried vaccine powder and 2'- fucosyllactose is 1:(0.1-0.4)；
Total viable count of Lactobacillus rhamnosus is no less than 10 in Lactobacillus rhamnosus freeze-dried vaccine powder11CFU/g。
3. being applied described in claim 1, which is characterized in that the composition is by Lactobacillus rhamnosus freeze-dried vaccine powder and 2'- rock algae
Glycosyl lactose composition；Wherein: the mass ratio of Lactobacillus rhamnosus freeze-dried vaccine powder and 2'- fucosyllactose is 1:0.4；Rhamnose
The total viable count of Lactobacillus rhamnosus is no less than 10 in lactobacillus freeze-dried vaccine powder11CFU/g。
4. a kind of baby formula milk powder containing the composition being made of Lactobacillus rhamnosus and 2'- fucosyllactose.
5. a kind of infant nutrient replenishers containing the composition being made of Lactobacillus rhamnosus and 2'- fucosyllactose.
6. infant nutrient replenishers according to claim 5, which is characterized in that by skimmed milk powder, PURE WHEY is low
Fructooligosaccharides, multi-vitamins, zinc citrate, calcium carbonate, soybean oil, casein sodium, isolated soy protein, 2'- fucosido
Lactose and Lactobacillus rhamnosus composition；The parts by weight of each raw material are as follows: 90 parts -100 parts of skimmed milk powder, PURE WHEY 35
- 40 parts of part, 10 parts -12 parts of oligofructose, 0.1 part -0.15 part of multi-vitamins, 0.25 part -0.3 part of zinc citrate, calcium carbonate
0.30 part -0.35 part, 3.5 parts -4.0 parts of soybean oil, 7.5 parts -8.0 parts of casein sodium, 3.2 part -3.5 of isolated soy protein
Part, 0.1 part -0.48 part of 2'- fucosyllactose, 1 part -1.2 parts of Lactobacillus rhamnosus freeze-dried vaccine powder；The Lactobacillus rhamnosus
Total viable count of Lactobacillus rhamnosus is no less than 10 in freeze-dried vaccine powder11CFU/g。
7. a kind of infant's diatery supplement containing the composition being made of Lactobacillus rhamnosus and 2'- fucosyllactose.
8. infant's diatery supplement according to claim 7, which is characterized in that by rice, fructose syrup, millet, adlay, jade
Rice, carrot, tomato, calcium gluconate, zinc pyrophosphate, multi-vitamins, oligofructose, galactooligosaccharide, lactase, albumen
Enzyme, Lactobacillus rhamnosus and 2'- fucosyllactose；The parts by weight of each raw material are as follows: 55 parts -65 parts of rice, fructose syrup 4
- 8 parts of part, 20 parts -22 parts of millet, 5 parts -8 parts of adlay, 10 parts -12 parts of corn, 6 parts -10 parts of carrot, 5 parts -8 parts of tomato, Portugal
10 parts -15 parts of grape Calciofon, 1.8 parts -2.5 parts of zinc pyrophosphate, 0.1 part -0.15 part of multi-vitamins, 4 parts -5 parts of oligofructose,
0.6 part -1.0 parts of galactooligosaccharide, 2 parts -3 parts of lactase, 1 part -2 parts of protease, 1.2 parts of Lactobacillus rhamnosus freeze-dried vaccine powder -
1.5 parts and 0.12 part -0.6 part of 2'- fucosyllactose；Lactobacillus rhamnosus is total in the Lactobacillus rhamnosus freeze-dried vaccine powder
Viable count is no less than 1011CFU/g。
9. a kind of probiotics preparation containing the composition being made of Lactobacillus rhamnosus and 2'- fucosyllactose.
10. probiotics preparation according to claim 9, which is characterized in that by Lactobacillus rhamnosus, 2'- fucosido cream
Sugar, oligofructose and resistant dextrin composition, the parts by weight of each raw material are as follows: 15-20 parts of Lactobacillus rhamnosus freeze-dried vaccine powder,
1.5-8 parts of 2'- fucosyllactose, 35-40 parts and resistant dextrin 30-40 parts of oligofructose；The Lactobacillus rhamnosus freeze-drying
Total viable count of Lactobacillus rhamnosus is no less than 10 in bacterium powder11CFU/g。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811585852.6A CN109528777A (en) | 2018-12-25 | 2018-12-25 | By the application for the composition that Lactobacillus rhamnosus and 2`- fucosyllactose form |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811585852.6A CN109528777A (en) | 2018-12-25 | 2018-12-25 | By the application for the composition that Lactobacillus rhamnosus and 2`- fucosyllactose form |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109528777A true CN109528777A (en) | 2019-03-29 |
Family
ID=65857179
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811585852.6A Pending CN109528777A (en) | 2018-12-25 | 2018-12-25 | By the application for the composition that Lactobacillus rhamnosus and 2`- fucosyllactose form |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109528777A (en) |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110122865A (en) * | 2019-06-03 | 2019-08-16 | 哈尔滨工业大学 | A kind of supplementary food for infants and preparation method thereof adding breast milk oligosaccharide |
| CN113509495A (en) * | 2021-08-03 | 2021-10-19 | 东北农业大学 | Application of lactobacillus rhamnosus in relieving intestinal inflammation |
| CN113796546A (en) * | 2021-09-13 | 2021-12-17 | 合生元（广州）健康产品有限公司 | Breast milk oligosaccharide composition for improving intestinal barrier function and application thereof |
| CN114246339A (en) * | 2020-09-25 | 2022-03-29 | 内蒙古伊利实业集团股份有限公司 | Composition and application thereof in preparation of product for improving intestinal immunity |
| CN114401642A (en) * | 2019-09-18 | 2022-04-26 | 科汉森母乳低聚糖股份有限公司 | Cereal compositions containing human milk oligosaccharides |
| CN114504107A (en) * | 2020-11-16 | 2022-05-17 | 内蒙古伊利实业集团股份有限公司 | Composition containing lactobacillus rhamnosus and breast milk oligosaccharide and application thereof |
| CN115011532A (en) * | 2022-08-08 | 2022-09-06 | 东北农业大学 | Lactobacillus paracasei JY062 preparation and preparation method and application thereof |
| CN115414392A (en) * | 2022-11-03 | 2022-12-02 | 东北农业大学 | Composition containing lactobacillus rhamnosus JL1 metagenesis powder, preparation method and application |
| CN115836733A (en) * | 2022-12-19 | 2023-03-24 | 澳优乳业（中国）有限公司 | Application of oligosaccharide in preparation of product for regulating intestinal flora |
| CN115868631A (en) * | 2022-12-19 | 2023-03-31 | 澳优乳业（中国）有限公司 | Composition for promoting intestinal health and application and product thereof |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104023560A (en) * | 2011-08-29 | 2014-09-03 | 雅培制药有限公司 | Human Milk Oligosaccharides For Preventing Injury And/Or Promoting Healing Of The Gastrointestinal Tract |
| US20160296540A1 (en) * | 2013-11-15 | 2016-10-13 | Nestec S.A. | Compositions for use in the prevention or treatment of necrotizing enterocolitis in infants and young children |
| CN108135944A (en) * | 2014-11-25 | 2018-06-08 | 伊夫罗生物科学公司 | Probiotics and prebiotic compositions and its method and purposes for adjusting microorganism group |
| CN108450555A (en) * | 2018-02-01 | 2018-08-28 | 澳优乳业（中国）有限公司 | A kind of shield tooth infant's formula milk and preparation method thereof |
| CN108935698A (en) * | 2018-09-11 | 2018-12-07 | 内蒙古伊利实业集团股份有限公司 | A kind of alimentation composition preventing baby diarrhea disease and application |
-
2018
- 2018-12-25 CN CN201811585852.6A patent/CN109528777A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104023560A (en) * | 2011-08-29 | 2014-09-03 | 雅培制药有限公司 | Human Milk Oligosaccharides For Preventing Injury And/Or Promoting Healing Of The Gastrointestinal Tract |
| US20160296540A1 (en) * | 2013-11-15 | 2016-10-13 | Nestec S.A. | Compositions for use in the prevention or treatment of necrotizing enterocolitis in infants and young children |
| CN108135944A (en) * | 2014-11-25 | 2018-06-08 | 伊夫罗生物科学公司 | Probiotics and prebiotic compositions and its method and purposes for adjusting microorganism group |
| CN108450555A (en) * | 2018-02-01 | 2018-08-28 | 澳优乳业（中国）有限公司 | A kind of shield tooth infant's formula milk and preparation method thereof |
| CN108935698A (en) * | 2018-09-11 | 2018-12-07 | 内蒙古伊利实业集团股份有限公司 | A kind of alimentation composition preventing baby diarrhea disease and application |
Non-Patent Citations (3)
| Title |
|---|
| ZHUO-TENG YU 等: ""Utilization of major fucosylated and sialylated human milk oligosaccharides by isolated human gut microbes"", 《GLYCOBIOLOGY》 * |
| 杨文君等: ""2’-岩藻基乳糖对益生菌定殖及抗炎能力的影响"", 《食品工业科技》 * |
| 高侃等: "《中国畜牧兽医学会动物营养学分会第七届中国饲料营养学术研讨会论文集》", 31 October 2014, 中国农业大学出版社 * |
Cited By (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110122865A (en) * | 2019-06-03 | 2019-08-16 | 哈尔滨工业大学 | A kind of supplementary food for infants and preparation method thereof adding breast milk oligosaccharide |
| CN110122865B (en) * | 2019-06-03 | 2022-02-08 | 哈尔滨工业大学 | Infant auxiliary food added with breast milk oligosaccharide and preparation method thereof |
| CN114401642A (en) * | 2019-09-18 | 2022-04-26 | 科汉森母乳低聚糖股份有限公司 | Cereal compositions containing human milk oligosaccharides |
| CN114246339A (en) * | 2020-09-25 | 2022-03-29 | 内蒙古伊利实业集团股份有限公司 | Composition and application thereof in preparation of product for improving intestinal immunity |
| CN114504107A (en) * | 2020-11-16 | 2022-05-17 | 内蒙古伊利实业集团股份有限公司 | Composition containing lactobacillus rhamnosus and breast milk oligosaccharide and application thereof |
| CN114504107B (en) * | 2020-11-16 | 2023-08-29 | 内蒙古伊利实业集团股份有限公司 | Composition containing lactobacillus rhamnosus and breast milk oligosaccharide and application thereof |
| CN113509495A (en) * | 2021-08-03 | 2021-10-19 | 东北农业大学 | Application of lactobacillus rhamnosus in relieving intestinal inflammation |
| CN113796546A (en) * | 2021-09-13 | 2021-12-17 | 合生元（广州）健康产品有限公司 | Breast milk oligosaccharide composition for improving intestinal barrier function and application thereof |
| CN115011532A (en) * | 2022-08-08 | 2022-09-06 | 东北农业大学 | Lactobacillus paracasei JY062 preparation and preparation method and application thereof |
| CN115414392A (en) * | 2022-11-03 | 2022-12-02 | 东北农业大学 | Composition containing lactobacillus rhamnosus JL1 metagenesis powder, preparation method and application |
| CN115836733A (en) * | 2022-12-19 | 2023-03-24 | 澳优乳业（中国）有限公司 | Application of oligosaccharide in preparation of product for regulating intestinal flora |
| CN115868631A (en) * | 2022-12-19 | 2023-03-31 | 澳优乳业（中国）有限公司 | Composition for promoting intestinal health and application and product thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109528777A (en) | By the application for the composition that Lactobacillus rhamnosus and 2`- fucosyllactose form | |
| CN105146614B (en) | A kind of functional calcium fruit ferment, enzyme beverage and its production method | |
| CN105167072B (en) | A kind of production method of feature matrimony vine ferment and its product | |
| CN104509864B (en) | A kind of have nutritional health food improving gastrointestinal function and preparation method thereof | |
| CN105039217B (en) | A kind of hypoglycemic probiotics preparation and preparation method thereof | |
| CN109666615A (en) | A kind of probiotic composition and its application | |
| CN106619743A (en) | Probiotic solid drink with hypoglycaemic effect and preparation method of probiotic solid drink | |
| CN108112996A (en) | A kind of alimentation composition for controlling diabetes B crowd hyperglycaemia and improving immunity | |
| CN109628358A (en) | A kind of compound probiotic and its application | |
| KR101539382B1 (en) | Food composition for improvement of bowel function and relief of constipation | |
| CN108244252A (en) | Probiotics multielement protein powder and preparation method thereof | |
| CN110338402A (en) | A kind of compound probiotic powder and preparation method thereof | |
| CN104642870A (en) | Prebiotics composition | |
| CN106858132A (en) | It is a kind of to promote finishing period feed of laying hen Development of Digestive Organs and preparation method thereof | |
| CN108294231A (en) | It is suitble to the nutritional staple food of patients with diabetes mellitus | |
| CN104721652A (en) | Lactobacillus fermented barley meal as well as preparation method and application thereof | |
| CN105982009A (en) | Composition for regulating human body intestinal micro-ecology | |
| CN109528814A (en) | A kind of probiotics and its preparation method and application of lactobacillus-fermented Radix Astragali | |
| CN101965950A (en) | Unpolished rice ferment nutritional steamed bread and making method thereof | |
| JP3644500B2 (en) | Method for producing mushroom lactic acid fermented liquid and mushroom lactic acid fermented liquid produced therefrom | |
| CN105802876B (en) | A kind of composite probiotics ferment clover tender shoots powder preparation and its preparation method and application | |
| CN109527091A (en) | The meal replacement powder and preparation method that a kind of suitable hyperglycemia, hypertension and people with hyperlipidemia are taken | |
| CN100360179C (en) | Medicine for treating infantile anorexia | |
| CN108294232A (en) | Nutritional staple food with function of blood sugar reduction | |
| KR102098998B1 (en) | Medicinal herbs composition for enhancing immune activity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |